Will Morton[email protected]Molecular ImagingPET/CT guides treatment in men with recurrent prostate cancerF-18 fluciclovine and Ga-68 PSMA-11 PET/CT have similar benefits for sRT planning, in terms of improving cancer control without increased toxicity.June 30, 2026CTHospital resources tied to AI adoption for stroke detectionNTAP-billed AI use was most common in episodes with CT imaging, at comprehensive stroke centers, and in facilities with ≥1000 beds.June 26, 2026Interventional'Supermajority' emerges among interventional radiologistsThe percentage of those with a super-majority (>90%) of IR-related work more than doubled between 2008 and 2023.June 26, 2026CTSocioeconomic factors shape lung cancer screening burdenDifferences in patient experience were closely linked to social and economic factors.June 25, 2026MRICardiac MRI variables boost heart failure predictionSixteen key cardiac MRI variables improved risk prediction.June 23, 2026Molecular ImagingNew PET tracer shows promise for guiding pancreatic cancer therapyThe radiotracer is designed to identify pancreatic tumors eligible for paired therapy with cancer-killing actinium-225 (Ac-225) NMT25.June 19, 2026Digital X-RayPrunes not likely to improve bone health in menThe findings are contrary to similar studies in women.June 16, 2026Nuclear MedicineNew immuno-PET tracer shows promise in prostate cancerCompared to conventional imaging, Zr-89 DFO-YS5 PET identified additional lesions.June 15, 2026Molecular ImagingPSMA-PET/CT halves biopsy rate in prostate cancer patientsA majority of men with equivocal findings on MRI are found on biopsy to have either no cancer or clinically insignificant disease.June 11, 2026Molecular ImagingEarly FAPI-PET scans match 60-minute scans for lung cancer stagingBy convention, most molecular imaging tracers such as F-18 FDG are injected one hour prior to PET scans to allow time for uptake of the tracer by tumors.June 10, 2026Previous PagePage 2 of 56Next PageTop StoriesNuclear MedicineLutetium-177 PSMA-617 shows promise in earlier-stage prostate cancerAcross 14 studies, PSA50 response rates (the number of patients with at least a 50% drop in PSA) ranged from 44% to 100%.MRIMRI reveals links between brain aging, neuro disordersCTLDCT screening criteria miss majority of Korean lung cancer patientsMRIACR rolls out PE-RADS for pulmonary embolism careCTCT reveals severe craniofacial, ocular trauma from pager blasts
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
